Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Summary by Relevant Sections Allegations - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [3]. - The company's attempts to mitigate these issues through customer alerts were deemed insufficient, as design flaws persisted [3]. - There was an increased risk that customers would be advised to take existing Novum LVPs out of service, and Baxter might halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [3]. - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [4]. - Participation in the case does not require appointment as lead plaintiff, and there is no cost or obligation for shareholders to register [4]. Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Baxter International Inc. (NYSE: BAX) and certain of the Company’s senior executives for securities fraud after significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Baxter, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/baxter-international-inc ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Baxter International Inc. for misrepresentations regarding the safety of its Novum IQ Large Volume Pump, which allegedly concealed systemic issues that could lead to severe injury and death for patients [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Baxter's common stock between February 23, 2022, and July 30, 2025 [1]. - Defendants are accused of misrepresenting the safety of the Novum IQ Large Volume Pump, a device used for intravenous fluid delivery [2]. - The lawsuit highlights that systemic issues were concealed, putting patients at risk [2]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file papers by December 15, 2025 [3]. - Serving as lead plaintiff allows representation of other class members in directing the litigation, but recovery does not require this role [3]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times [4]. - It has also been listed in The Legal 500 for sixteen consecutive years [4].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements regarding the safety and functionality of its Novum IQ Large Volume Pump [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled "Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc." and covers investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Baxter - The lawsuit alleges that Baxter's Novum IQ Large Volume Pump had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in the company's stock price [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek appointment as lead plaintiff [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and functionality of its Novum IQ Large Volume Pump, which reportedly has systemic defects that pose serious risks to patients [3][4]. Summary by Sections Class Action Lawsuit Details - The lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the class action [1]. Allegations Against Baxter - Baxter allegedly made false or misleading statements and failed to disclose significant issues with the Novum IQ LVP, including systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - The company was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues were deemed inadequate, as design flaws persisted, continuing to harm patients [3]. Impact on Stock Price - Following Baxter's announcement on July 31, 2025, to pause shipments and installations of the Novum LVP, the company's stock price fell by more than 22% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, exposing patients to serious injury or death [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares during the class period (February 23, 2022, to July 30, 2025) and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Baxter International Inc. (NYSE: BAX) and certain of the Company’s senior executives for securities fraud after significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Baxter, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/baxter-international-inc ...

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][2]. Allegations - The complaint alleges that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple malfunctions, injuries, and deaths related to the Novum LVP but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVP were claimed to be materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, that Baxter would suspend all new Novum LVP sales, the company's stock price dropped by 22.4%, closing at $21.76 [3]. Next Steps for Shareholders - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by December 15, 2025 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Company Background - Robbins LLP, the firm handling the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].

LOS ANGELES--(BUSINESS WIRE)--Baxter International Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – BAX. ...

Core Points - A class action lawsuit has been filed against Baxter International Inc. for alleged violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit claims that Baxter made false and misleading statements regarding its supply chain issues, which were concealed from investors [4] - Investors who purchased Baxter's securities between May 25, 2022, and February 8, 2023, are encouraged to participate in the lawsuit [2] Company Information - Baxter is accused of misleading investors about its ability to maintain a strong supply chain amidst global challenges [4] - The company's projected earnings were deemed misleading, leading to investor damages once the truth was revealed [4] Legal Context - The class action lawsuit is being represented by the Schall Law Firm, which specializes in securities class action lawsuits and shareholder rights litigation [5] - Investors are advised to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3]